DOCSLIB.ORG

2012-2015 Ryan White Part B Program Comprehensive Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2012-2015 Ryan White Part B Program Comprehensive Plan 2012-2015 Ryan White Part B Program Comprehensive Plan Table of Contents Acronyms ............................................................................................................................... 1 Acknowledgements ................................................................................................................ 5 Introduction ............................................................................................................................ 6 WV Comprehensive Planning Process .......................................................................... 6 Executive Summary ............................................................................................................... 7 1. Where Are We Now: What is our Current System of Care? ................................... 8 HIV/AIDS In West Virginia-Epidemiologic Trends ..................................................... 8 Unmet Need ................................................................................................................. 24 2010 Unmet Need Framework Report ......................................................................... 27 Early Identification of Individuals with HIV/AIDS (EIIHA) ...................................... 43 Prevention Programs .................................................................................................... 49 Partner Services ........................................................................................................... 50 Continuum of Care ....................................................................................................... 52 2011 HIV Care and Treatment State and Federal Expenditures .................................. 53 Table of 2011 HIV Care and Treatment Expenditures ................................................ 53 Current System of Care ................................................................................................ 55 Core and Support Services Provided in WV................................................................ 58 Resource Inventory ...................................................................................................... 61 Ryan White Funded Service Providers Serving West Virginia ................................... 62 HIV / AIDS Prevention Community Based Organizations ......................................... 64 Needs Assessment ........................................................................................................ 69 Prevention Needs ......................................................................................................... 78 Statewide Coordinated Statement of Need .................................................................. 79 Over- Arching Issues ................................................................................................... 80 Care and Treatment ...................................................................................................... 81 Medications .................................................................................................................. 83 HIV/HCV Testing ........................................................................................................ 84 Substance Abuse .......................................................................................................... 84 Oral Health ................................................................................................................... 84 Mental Health............................................................................................................... 84 Ensuring PLWHA Stay in Care ................................................................................... 85 HIV Related Legislation .............................................................................................. 85 Prevention .................................................................................................................... 85 Training / Capacity Building ....................................................................................... 86 Statewide Collaboration ............................................................................................... 86 Corrections ................................................................................................................... 86 Disparities in Access to Care ....................................................................................... 86 Barriers to Care ............................................................................................................ 87 Gaps in Care ................................................................................................................. 88 2. Where Do We Need to Go: What is Our Vision of An Ideal System? .................. 92 Medical Case Management .......................................................................................... 93 Drug Reimbursement (Cost Sharing)........................................................................... 94 Outpatient / Ambulatory Care ...................................................................................... 95 Health Insurance .......................................................................................................... 96 Oral Health ................................................................................................................... 96 Mental Health............................................................................................................... 97 Substance Abuse .......................................................................................................... 98 Transportation .............................................................................................................. 98 Care and Treatment ...................................................................................................... 99 Medications ................................................................................................................ 100 HIV/HCV Testing and Education .............................................................................. 100 Substance Abuse ........................................................................................................ 101 Oral Health ................................................................................................................. 101 Mental Health............................................................................................................. 101 Ensuring PLWHA Stay in Care ................................................................................. 101 Long Term Goals ....................................................................................................... 102 3. How Will We Get There: How Does our System Need to Change to Assure Availability of and Accessibility to Core Services? ............................................... 103 WV FY 2012 IMPLEMENTATION PLAN ............................................................. 106 4. How Will We Monitor Our Progress: How Will We Evaluate Our Progress in Meeting Our Short-and-Long Term Goals? .......................................................... 109 Planned Clinical Quality Management Activities...................................................... 110 Description of ADAP Quality Management Program ............................................... 111 Monitoring Progress of the Comprehensive Plan ...................................................... 112 Acronyms ACA Affordable Care Act ACTG AIDS Clinical Trials Group ADAP AIDS/HIV Drug Assistance Program ADR ADAP Data Report AETC AIDS Education Training Center AHP Advancing HIV Prevention or also used as abbreviation for HIV/AIDS Program AHPI Advancing HIV Prevention Initiative AIDS Acquired Immune Deficiency Syndrome AN AIDS Network AODA Alcohol and other Drug Abuse APC AIDS Prevention Center ARV Antiretroviral ASO AIDS Service Organization ATF AIDS Task Force AZT Azidothymidine (chemical name for Zidovudine, brand name for Retrovir BHC Black Health Coalition BMS Bureau of Medical Services BRFSS Behavioral Risk Factor Surveillance Survey CAMC Charleston Area Medical Center CAIR Center for AIDS Intervention Research CAPS Center for AIDS Prevention Studies (University of California, San Francisco) CARE Act Ryan White Comprehensive Resources Emergency Act, now known as the Ryan White HIV/AIDS Treatment Extension Act of 2009 CAS Client Assessment Sheet CBA Capacity Building Assistance CBO Community Based Organization CD4 Cluster of differentiation 4 (T helper cell) CDC Centers for Disease Control and Prevention CEO Chief Executive Office CHC Community Health Centers CLD Client Level Data CLI Community Level Intervention CMS Centers for Medicare and Medicaid Services (Federal) COBRA Consolidate Omnibus Reconciliation Act CPG Community Planning Group CQI Continuous Quality Improvement CTR Counseling, Testing & Referral DD Developmental Disabilities DEBIs Diffusion of Effective Behavioral Interventions DHHR Depart of Health and Human Resources (West Virginia) DHHS Department of Health and Human Services DNA Deoxyribonucleic acid DOC Department of Corrections DSHH Division of STD/HIV/Hepatitis 2012-2015 West Virginia Ryan White Part B Program Comprehensive Plan Page 1 EBIs Effective Behavioral Interventions EFA Emergency Financial Assistance eHARS Enhanced HIV/AIDS Reporting System EIIHA Early Identification of Individuals with HIV/AIDS EIS Early Intervention Services EMA Eligible Metropolitan
Load more

Recommended publications
  • Fuel Properties Comparison
    Alternative Fuels Data Center Fuel Properties Comparison Compressed Liquefied Low Sulfur Gasoline/E10 Biodiesel Propane (LPG) Natural Gas Natural Gas Ethanol/E100 Methanol Hydrogen Electricity Diesel (CNG) (LNG) Chemical C4 to C12 and C8 to C25 Methyl esters of C3H8 (majority) CH4 (majority), CH4 same as CNG CH3CH2OH CH3OH H2 N/A Structure [1] Ethanol ≤ to C12 to C22 fatty acids and C4H10 C2H6 and inert with inert gasses 10% (minority) gases <0.5% (a) Fuel Material Crude Oil Crude Oil Fats and oils from A by-product of Underground Underground Corn, grains, or Natural gas, coal, Natural gas, Natural gas, coal, (feedstocks) sources such as petroleum reserves and reserves and agricultural waste or woody biomass methanol, and nuclear, wind, soybeans, waste refining or renewable renewable (cellulose) electrolysis of hydro, solar, and cooking oil, animal natural gas biogas biogas water small percentages fats, and rapeseed processing of geothermal and biomass Gasoline or 1 gal = 1.00 1 gal = 1.12 B100 1 gal = 0.74 GGE 1 lb. = 0.18 GGE 1 lb. = 0.19 GGE 1 gal = 0.67 GGE 1 gal = 0.50 GGE 1 lb. = 0.45 1 kWh = 0.030 Diesel Gallon GGE GGE 1 gal = 1.05 GGE 1 gal = 0.66 DGE 1 lb. = 0.16 DGE 1 lb. = 0.17 DGE 1 gal = 0.59 DGE 1 gal = 0.45 DGE GGE GGE Equivalent 1 gal = 0.88 1 gal = 1.00 1 gal = 0.93 DGE 1 lb. = 0.40 1 kWh = 0.027 (GGE or DGE) DGE DGE B20 DGE DGE 1 gal = 1.11 GGE 1 kg = 1 GGE 1 gal = 0.99 DGE 1 kg = 0.9 DGE Energy 1 gallon of 1 gallon of 1 gallon of B100 1 gallon of 5.66 lb., or 5.37 lb.
    [Show full text]
  • Automotive Gasoline Cas # 8006-61-9
    AUTOMOTIVE GASOLINE CAS # 8006-61-9 Agency for Toxic Substances and Disease Registry ToxFAQs September 1996 This fact sheet answers the most frequently asked health questions (FAQs) about automobile gasoline. For more information, call the ATSDR Information Center at 1-888-422-8737. This fact sheet is one in a series of summaries about hazardous substances and their health effects. This information is important because this substance may harm you. The effects of exposure to any hazardous substance depend on the dose, the duration, how you are exposed, personal traits and habits, and whether other chemicals are present. SUMMARY: Exposure to automotive gasoline most likely occurs from breathing its vapor at a service station while filling a car’s fuel tank. At high levels, automotive gasoline is irritating to the lungs when breathed in and irritating to the lining of the stomach when swallowed. Exposure to high levels may also cause harmful effects to the nervous system. Automotive gasoline has been found in at least 23 of the 1,430 National Priorities List sites identified by the Environmental Protection Agency (EPA). What is automotive gasoline? � Other chemicals in gasoline dissolve in water after spills to surface waters or underground storage tank leaks into (Pronounced ô ) the groundwater. 't;-miftlv gasf;-len' The gasoline discussed in this fact sheet is automotive used � In surface releases, most chemicals in gasoline will prob­ as a fuel for engines in cars. Gasoline is a colorless, pale brown, or ably evaporate; others may dissolve and be carried away by water; a few will probably stick to soil.
    [Show full text]
  • Recognizing Drug Use in Adolescents
    RecognizingRecognizingRecognizing DrugDrugDrug UseUseUse ininin AdolescentsAAdolescentsdolescents A Quick Guide for Caregivers and Adults 1 RecognizingRecognizing DrugDrug UseUse inin AdolescentsAdolescents A Quick Guide for Caregivers and Adults Concerned caregivers and adults play an important role in ensuring that youth receive adequate help. However, at times it is hard to tell that youth are developing a problem with alcohol and drugs. This guide summarizes the signs of intoxication, use, and abuse commonly reported by substance users. It is important to recognize, however, that some of the behaviors and experiences described in this booklet may also be present among adolescents who are not using substances. For this reason, when deciding on the best course of action to obtain help for your teenager, make sure to talk with your teenager, gather as much information as possible, and consult with health professionals available in your community. i Alcohol and drug use poses significant risks for the healthy development of adolescents, yet substances of abuse are often readily accessible at school, at home, and in the community. This guide has been developed to facilitate early identification of substance use problems in youth. Included is information about common drugs of abuse and key information to help identify youth at risk. Recognizing the signs of use includes how a teenager might look, act, and feel while intoxicated as well as drug para- phernalia and language associated with each drug. g Signs of intoxication vary by type of
    [Show full text]
  • Estimates of Nitrous Oxide Emissions from Motor Vehicles and the Effects of Catalyst Composition and Aging
    ESTIMATES OF NITROUS OXIDE EMISSIONS FROM MOTOR VEHICLES AND THE EFFECTS OF CATALYST COMPOSITION AND AGING Contract No. 02-313 STATE OF CALIFORNIA AIR RESOURCES BOARD Final Report Prepared by Arthur M. Winer, Ph.D. Principal Investigator Environmental Health Sciences Department and Environmental Science and Engineering Program School of Public Health University of California, Los Angeles, California, 90095 (310) 206-1278 Eduardo Behrentz, D.Env. Co-Investigator Environmental Science and Engineering Program School of Public Health University of California, Los Angeles June 10, 2005 N2O Emissions from Motor Vehicles DISCLAIMER The statements and conclusions in this report are those of the contractor and not necessarily those of the California Air Resources Board. The mention of commercial products, their source, or their use in connection with material reported herein is not to be constructed as actual or implied endorsement of such products. i N2O Emissions from Motor Vehicles ii N2O Emissions from Motor Vehicles ACKNOWLEDGEMENTS The contributions of the California Air Resources Board staff, particularly Paul Rieger, who made invaluable suggestions and contributions throughout the project, and Hector Maldonado who acted as our Project Officer, were greatly appreciated. We also thank Richard Ling of the Monitoring and Laboratory Division who collected all emissions data from the 16th Vehicle Surveillance Program and who provided on-site training and support. We thank Margo Eaddy for her participation during the data collection process. We wish to acknowledge valuable contributions from Jerry Ho and Robin Lang of the Mobile Source Operations Division who provided logistical support during vehicle testing and data collection. We especially appreciated Shane Michael, the project’s Test Engineer, of the Mobile Source Operations Division for his professionalism and willingness to assist us throughout the study.
    [Show full text]
  • Volatile Solvents As Drugs of Abuse: Focus on the Cortico-Mesolimbic Circuitry
    Neuropsychopharmacology (2013) 38, 2555–2567 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Review Volatile Solvents as Drugs of Abuse: Focus on the Cortico-Mesolimbic Circuitry 1,2 ,1,2 Jacob T Beckley and John J Woodward* 1 2 Department of Neurosciences, Medical University of South Carolina, Charleston, SC, USA; Center for Drug and Alcohol Programs, Department of Psychiatry/Neurosciences, Medical University of South Carolina, Charleston, SC, USA Volatile solvents such as those found in fuels, paints, and thinners are found throughout the world and are used in a variety of industrial applications. However, these compounds are also often intentionally inhaled at high concentrations to produce intoxication. While solvent use has been recognized as a potential drug problem for many years, research on the sites and mechanisms of action of these compounds lags behind that of other drugs of abuse. In this review, we first discuss the epidemiology of voluntary solvent use throughout the world and then consider what is known about their basic pharmacology and how this may explain their use as drugs of abuse. We next present data from preclinical and clinical studies indicating that these substances induce common addiction sequelae such as dependence, withdrawal, and cognitive impairments. We describe how toluene, the most commonly studied psychoactive volatile solvent, alters synaptic transmission in key brain circuits such as the mesolimbic dopamine system and medial prefrontal cortex (mPFC) that are thought to underlie addiction pathology. Finally, we make the case that activity in mPFC circuits is a critical regulator of the mesolimbic dopamine system’s ability to respond to volatile solvents like toluene.
    [Show full text]
  • Locating and Estimating Sources of Methyl Chloroform
    EPA-454/R-93-045 LOCATING AND ESTIMATING AIR EMISSIONS FROM SOURCES OF METHYL CHLOROFORM Office of Air Quality Planning and Standards U.S. Environmental Protection Agency Research Triangle Park, North Carolina 27711 February 1994 DISCLAIMER This report has been reviewed by the Office of Air Quality Planning and Standards, and has been approved for publication. Any mention of tradenames or commercial products is not intented to constitute endorsement or recommendation for use. ii CONTENTS Section Page DISCLAIMER ..................................................... ii LIST OF FIGURES .................................................. v LIST OF TABLES ................................................... vi 1.0 PURPOSE OF DOCUMENT ..................................... 1-1 1.1 Reference for Section 1.0 ................................... 1-5 2.0 OVERVIEW OF DOCUMENT CONTENTS .......................... 2-1 2.1 References for Section 2.0 .................................. 2-5 3.0 BACKGROUND .............................................. 3-1 3.1 Nature of Pollutant ....................................... 3-1 3.2 Regulatory Actions Affecting Methyl Chloroform Production and Use .... 3-4 3.3 Overview of Production and Use .............................. 3-7 3.4 References for Section 3.0 ................................. 3-10 4.0 EMISSIONS FROM METHYL CHLOROFORM PRODUCTION ............ 4-1 4.1 Production Process Descriptions .............................. 4-2 4.1.1 Hydrochlorination of Vinyl Chloride ...................... 4-4 4.1.2 Hydrochlorination
    [Show full text]
  • Solvents/Inhalants Information for Health Professionals
    Solvents/Inhalants Information for Health Professionals Introduction Inhalants compromise a wide variety of vapours, gases, and aerosols that can be inhaled to induce psychoactive (mind-altering) effects. Unlike other drugs, inhalants are available as legal products with low costs and wide availability. Examples include commercial products such as nail polish remover, hair sprays, lighter fluid, cleaning fluids, vegetable frying pan lubricants, and spray paints. These chemicals can be sniffed or inhaled because they are gaseous at room temperature and pressure. “Inhalant” is a general term that includes all substances used in this way. Most inhalants are volatile solvents, which are liquids that easily vaporize at room temperature and can contain many different chemicals that may be psychoactive. The majority of these solvents are produced from petroleum and natural gas. They have an enormous number of industrial, commercial and household uses, and are found in automobile fuels, cleaning fluids, toiletries, adhesives and fillers, paints, paint thinners, felt-tip markers, and many other products. In addition to volatile solvents, aerosols (hair spray, paint spray) can be abused as inhalants. Other inhalants include the nitrites (amyl and butyl, “poppers”, “Rush”) and gases such as the anesthetics nitrous oxide (laughing gas) and ether. Inhalants can be breathed in through the nose or mouth in a variety of ways, including spraying aerosols directly into the nose or mouth, “sniffing” or "snorting” fumes from containers, inhaling from balloons filled with nitrous oxide, “huffing” from an inhalant-soaked rag stuffed in the mouth, or “bagging”- pouring the substance over a cloth or into a plastic bag and breathing in the vapours.
    [Show full text]
  • Toluene and Groundwater Toluene Toluene Is a Clear Liquid That Occurs Naturally in Crude Oil
    Toluene and Groundwater Toluene Toluene is a clear liquid that occurs naturally in crude oil. It is included in a group of chemicals often associated with petroleum known as BTEX, which stands for benzene, toluene, ethylbenzene, and xylenes. The chemicals in BTEX are commonly found in gasoline and petroleum products. Manufacturers also use toluene to make paints, polishes and lacquers, adhesives, nylon, plastics, and other chemicals. 1 Toluene in Minnesota Waters At locations with known groundwater contamination, toluene has been detected in approximately 17 percent of samples, with a maximum concentration of 22,000 µg/L.2 In groundwater not known to be impacted by a contamination source, toluene has been detected in approximately one percent of samples, with a maximum concentration of 0.35 µg/L.2 In surface water, toluene has been detected in approximately 23 percent of samples, with a maximum concentration of 0.61 µg/L.3 Toluene has been detected in approximately two percent of 9,852 drinking water samples collected in the last 10 years, with a maximum detection of 140 µg/L.4 Only one detection in the last ten years was above the MDH health-based guidance value of 70 ug/L. All detections have been below the Safe Drinking Water Act limit of 1,000 µg/L. *One microgram per liter (µg/L) is the same as one part per billion (ppb). MDH Guidance Value Based on available information, MDH developed a guidance value of 70 µg/L for toluene in drinking water. MDH does not use guidance values to regulate water quality, but they may be useful for situations in which no regulations exist.
    [Show full text]
  • Gasoline Safety Educator's Guide
    American Burn Association GASOLINE SAFETY Educator’s Guide A Community Fire and Burn Prevention Program Supported by the United States Fire Administration Federal Emergency Management Agency General Background Information • Selected gasoline-related injury statistics • Technical Background Fact Sheets for Community Distribution • Portable gasoline containers • Portable container and vehicle filling procedures • Small engines and gasoline powered equipment Static electricity and gasoline Automobile carburetors • Transporting and storing gasoline • Barbecue safety and Propane grill safety • Inappropriate uses of gasoline • First aid for exposure to gasoline References/Resources PowerPoint Slide Presentation with Instructor Comments Evaluation Form Community Fire & Burn Prevention Programs Gasoline Safety Campaign GENERAL BACKGROUND INFORMATION Gasoline, when ignited in a controlled manner to power engines, serves a very useful purpose. Because it is so commonplace, however, we sometimes take its presence for granted without realizing how dangerous it can be. The same quality of explosive ignition that makes gasoline so valuable as a fuel can cause terrible injuries when it is handled carelessly or used for a purpose for which it is not intended. Gasoline and other flammable liquid-related burns, however, are a preventable problem. These accidents are often associated with careless use (misuse) of gasoline. Most accidents occur in the summer months due to an increased use of gasoline for farming or recreational purposes (i.e. bonfires, burning leaves, boating, yard work, etc.). A lack of understanding of the explosive nature of gasoline by the general public seems to contribute to both its improper storage and misuse as a solvent, engine primer or fire starter. Gasoline burns decrease markedly in winter months except burns associated with carburetor priming to start cars.
    [Show full text]
  • Neurotoxicity and Mechanism of Toluene Abuse
    4MEDICAL SCIENTIFIC REVIEW Neurotoxicity and Mechanism of Toluene Abuse Daniel P. Eisenberg Albert Einstein College of Medicine Belfer Educational Center Bronx, New York 10461 ABSTRACT inhalant abuse ranging from 8% to 25% among high school students (Kurtzman et al., 2001). In addition, Toluene is one of the most produced and widely used more than half of those reporting a history of inhalant industrial solvents worldwide. It is a key ingredient in use have done so multiple times, and 77% state they many products used by inhalant abusers. Toluene is have abused inhalants for more than one year responsible not only for instant inebriation but also for (Newmark et al., 1998). devastating neurotoxicity and death in the chronic abusers. Despite its prevalence and associated morbidity The tremendous morbidity and mortality associated and mortality, very little is known about how this with this behavior are often under-appreciated. From volatile solvent enacts its neurotoxic actions. Recent 1987 to 1996 in Virginia alone, there were 39 inhalant- experimental evidence suggests that toluene does not related deaths (2 died abusing pure toluene or products act solely through the non-specific disruption of cell containing mostly toluene and several more died membranes as previously hypothesized. Instead, inves- abusing products that contained toluene as a key ingre- tigators have begun to describe a diverse and unique dient) (Bowen et al., 1999). Chronic toluene abuse can profile of neurotransmitter interactions that have cause irreversible renal, hepatic, cardiac, and pulmonary brought science closer to understanding the behavioral, toxicity (Marjot and McLeod, 1989; Schaumburg, 2000). cognitive, and psychiatric effects of toluene.
    [Show full text]
  • FILED JULY 12, 2016 in the Office of the Clerk of Court WA State Court of Appeals, Division Ill
    FILED JULY 12, 2016 In the Office of the Clerk of Court WA State Court of Appeals, Division Ill IN THE COURT OF APPEALS OF THE STATE OF WASHINGTON DIVISION THREE SHERRIE LENNOX, as Personal ) Representative of the ESTATE OF ) No. 33201-2-111 VIOLA WILLIAMS, ) ) Appellants, ) ) v. ) UNPUBLISHED OPINION ) LOURDES HEAL TH NETWORK a ) Washington non-profit corporation; ) BENTON COUNTY and FRANKLIN ) COUNTY, Washington municipal ) corporations, ) ) Respondents. ) ) ) ) FEARING, C.J. -Under RCW 71.05.120, an entity enjoys immunity from conduct related to the failure to involuntarily commit a mental health patient, but not for gross negligent acts. On the basis of this immunity, the trial court dismissed on summary judgment claims against Lourdes Health Network and Benton and Franklin Counties Crisis Response Unit for the murder of Viola Williams by her grandson, Adam Williams, No. 33201-2-111 Lennox v. Lourdes Health Network a mental health patient. We affirm the summary dismissal in favor of the Crisis Response Unit and reverse the dismissal in favor of Lourdes Health Network. FACTS The background to Sherrie Lennox's lawsuit against Lourdes Health Network and the Crisis Response Unit concerns the mental illness of Adam Williams and treatment for the illness. From the age of eleven, Adam Williams struggled with attention deficit hyperactivity disorder, major depression, and substance abuse. He began using methamphetamine, marijuana, and alcohol at age twelve. He abused inhalants such as gasoline and glue, hallucinogenic mushrooms, lysergic acid diethylamide (LSD) and other drugs, and participated in substance abuse treatment several times. By the age of sixteen, Williams sat in juvenile detention sixteen times, with ten convictions for crimes such as malicious mischief, forgery, residential burglary, and eluding the police.
    [Show full text]
  • The Science of Addiction
    Drugs, Brains, and Behavior The Science of Addiction Image: White Matter Fibers, Parietal Areas • www.humanconnectomeproject.org This publication is in the public domain and may be used or reproduced in its entirety without permission from NIDA. Citation of the source is appreciated. NIH Pub No. 14-5605 Printed April 2007 Revised February 2008, August 2010, July 2014 CONTENTS Preface ............................................................................................................................................................................ 1 Introduction .................................................................................................................................................................... 3 I. Drug Abuse and Addiction ........................................................................................................................................... 5 II. Preventing Drug Abuse: The Best Strategy ................................................................................................................. 11 III. Drugs and the Brain ................................................................................................................................................ 15 IV. Addiction and Health ................................................................................................................................................ 21 V. Treatment and Recovery ...........................................................................................................................................
    [Show full text]